Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (9415)	11/4/2002 12:27:24 PM
From: Evan	Read Replies (1) \| Respond to of 48461

BMKS: What about these numbers? Share-Related Items Market Capitalization $514.0K Shares Outstanding 128.6M Float 56.6M Sales (ttm) $998.0K EBITDA (ttm) $133.0K

To: Bucky Katt who wrote (9415)	11/4/2002 12:38:08 PM
From: BW	Read Replies (1) \| Respond to of 48461

yep, seems you could have throw a dart and the rats and got at least 50% the past couple weeks. I'm taking profits too, going to the dark side today via some -2x funds. this rally was great but completely fabricated. my PUMA might hit 200% today, just 2 more cents <g>

To: Bucky Katt who wrote (9415)	11/4/2002 12:57:25 PM
From: BW	Respond to of 48461

TRIB news - Trinity Biotech Receives FDA Clearance for AMAX Destiny (TM) Hemostasis Analyzer and Appoints New CFO Monday November 4, 12:47 pm ET DUBLIN, Ireland, Nov. 4 /PRNewswire-FirstCall/ -- Trinity Biotech plc (Nasdaq: TRIB - News) today announced that it has received US Food & Drug Administration (FDA) marketing clearance for its new hemostasis analyzer AMAX Destiny(TM). The AMAX Destiny(TM) is an exciting new instrument which opens an additional segment of the $700m hemostasis market for Trinity Biotech. It offers high-end technology on a small, low cost platform, giving smaller clinical laboratories the ability to process hemostasis tests formerly offered only in large reference laboratories. The Destiny (TM) analyzer will be manufactured in Trinity Biotech's instrumentation manufacturing facility in Lemgo, Germany. It is a state-of-the-art hemostasis analyzer with many new features to simplify hemostasis testing. It is a fast, easy to use, accurate and reliable analyzer which offers the flexibility to perform both optical and mechanical clot, chromogenic and immunoturbidimetric based assays simultaneously. With its Windows driven software, the AMAX Destiny (TM) requires minimal programming, has verification of sample positioning, one-touch reagent management and many more features to simplify hemostasis testing. Ronan O'Caoimh, Trinity Biotech CEO commented: "We are extremely pleased to receive FDA clearance of the AMAX Destiny (TM) hemostasis analyzer. This is the culmination of three years of intensive research and development efforts and will provide Trinity Biotech with a highly competitive hemostasis instrumentation portfolio which includes the semi-automated KC1 Delta and KC4 Delta and the fully automated AMAX 200 and AMAX 400. With our worldwide installed base of well over 500 instruments, our comprehensive range of specialty hemostasis reagents from Biopool and our broad range of routine reagents, standards and controls from Sigma, Trinity Biotech is well placed to experience substantial organic growth in our hemostasis business in the coming years." The Company also announced today that Mr. Rory Nealon is joining the Company as Chief Financial Officer effective 31st December 2002. Mr. Nealon, a Chartered Accountant, currently acts as Finance Director of Conduit plc, a telecommunications service provider quoted on the Irish and German stock markets. Previously he was a manager with both Allied Irish Bank and Arthur Andersen. Mr. Nealon replaces Mr. Maurice Hickey who is leaving the Company at the end of the year to pursue other business interests. Ronan O' Caoimh, CEO commented: "We wish to thank Maurice for his significant contribution to the development of Trinity and to wish him every success in the future."